NDA 203050 · Avyxa Holdings
Posfrea
Palonosetron Hydrochloride · Intravenous
Last checked: Nov 20, 2026Latest source record: Apr 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Mar 1, 2016
Approved uses
2
Original approval plus efficacy supplements
Registered trials
153
41 Phase 3, 11 recruiting
FAERS reports
3,601
3,304 serious, 566 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 29, 2025.
POSFREA is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, POSFREA is recommended even where the incidence of postoperative nausea and/or vomiting is low. POSFREA is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. POSFREA is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 )
Mechanism: Palonosetron is a 5-HT 3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT 3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 16, 2025 Supplement 3 · Efficacy LabelLetter
- Mar 1, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelReviewLetter
2 products under this application
- POSFREA · PALONOSETRON HYDROCHLORIDE EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) · SOLUTION, INTRAVENOUS · Discontinued
- POSFREA · PALONOSETRON HYDROCHLORIDE EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Palonosetron" as an intervention, any sponsor and status, largest first.
Vanderbilt UniversityAcademic, hospital or other
NCT02625181 · 27,034 participants · Start Jul 2016 · Primary completion Nov 2, 2017
Drug: Propofol; Sevoflurane and 28 more · For: Postoperative Nausea and Vomiting
Sites: Nashville, Tennessee
- An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingPivotal-lookingCompleted
Helsinn Healthcare SAIndustry
NCT01339260 · 1,455 participants · Start Apr 2011 · Primary completion Nov 2012
Drug: Netupitant and Palonosetron; Palonosetron and 1 more · For: Chemotherapy-Induced Nausea and Vomiting
Sites: Anniston, Alabama; Muscle Shoals, Alabama; Hot Springs, Arkansas · 172 sites in all
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for CancerPivotal-lookingCompleted
Heron TherapeuticsIndustry
NCT00343460 · 1,428 participants · Start Jun 2006 · Primary completion Sep 2008
Drug: APF530; dexamethasone and 1 more · For: Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
Sites: Anniston, Alabama; Glendale, Arizona; Tucson, Arizona · 52 sites in all
- Treatment of Refractory Nausea and Vomiting in Patients With Breast CancerPivotal-lookingCompleted
University of Rochester NCORP Research BaseAcademic, hospital or other
NCT03367572 · 1,363 participants · Start Apr 19, 2018 · Primary completion Apr 13, 2024
Drug: Dexamethasone; Netupitant/Palonosetron Hydrochloride and 2 more · For: Breast Carcinoma
Sites: Honolulu, Hawaii; Decatur, Illinois; New Orleans, Louisiana · 18 sites in all
- Triple Therapy for Postoperative Nausea and Vomiting in Laparoscopic Gastrointestinal SurgeryPivotal-lookingCompleted
Sixth Affiliated Hospital, Sun Yat-sen UniversityAcademic, hospital or other
NCT04853147 · 1,154 participants · Start Apr 27, 2021 · Primary completion Apr 13, 2022
Drug: palonosetron, dexamethasone, and fosaprepitant dissolved in 0.9% NaCl; palonosetron, dexamethasone, and 0.9% NaCl · For: C.Surgical Procedure; Gastrointestinal
Sites: Guangzhou, China
- Comparative Study of Palonosetron With Granisetron as a Control in Patients Receiving Highly Emetogenic ChemotherapyPivotal-lookingCompleted
Taiho Pharmaceutical Co., Ltd.Industry
NCT00359567 · 1,140 participants (planned) · Start Jul 2006 · Primary completion May 2007
Drug: palonosetron; granisetron hydrochloride · For: Chemotherapy-Induced Nausea and Vomiting
Sites: 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan
Xijing HospitalAcademic, hospital or other
NCT05690802 · 1,060 participants (planned) · Start May 16, 2022 · Primary completion May 30, 2027
Drug: Palonosetron hydrochloride capsules · For: Nausea and Vomiting
Sites: Xi'an, China
- Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast CancerPivotal-lookingNot yet recruiting
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT05841849 · 1,028 participants (planned) · Start Jul 2023 · Primary completion Jul 2028
Drug: Aprepitant; Palonosetron and 1 more · For: Breast Cancer; Chemotherapy-induced Nausea and Vomiting
Sites: Hanzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea443
- diarrhoea264
- fatigue264
- vomiting263
- febrile neutropenia259
- neutropenia254
- alopecia229
- anaemia203
- dyspnoea201
- off label use201
- decreased appetite191
- death190
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 7 |
| 2005 | 21 |
| 2006 | 13 |
| 2007 | 18 |
| 2008 | 28 |
| 2009 | 24 |
| 2010 | 27 |
| 2011 | 38 |
| 2012 | 101 |
| 2013 | 69 |
| 2014 | 120 |
| 2015 | 159 |
| 2016 | 170 |
| 2017 | 189 |
| 2018 | 322 |
| 2019 | 244 |
| 2020 | 207 |
| 2021 | 317 |
| 2022 | 325 |
| 2023 | 282 |
| 2024 | 287 |
| 2025 | 393 |
| 2026 | 240 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S, Rücker G, Eberhart LH, et al. · Cochrane Database Syst Rev 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Palonosetron.
Siddiqui MA, Scott LJ · Drugs 2004 · Clinical Trial, Randomized Controlled Trial
- Interventions for the prevention of acute phase chemotherapy-induced nausea and vomiting in adult and pediatric patients: a systematic review and meta-analysis.
Patel P, Robinson PD, Wahib N, et al. · Support Care Cancer 2022 · Meta-Analysis, Systematic Review
- Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H, Abe M, Tokuyama O, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V, Adams A, Haque M, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Fosaprepitant for postoperative nausea and vomiting in patients undergoing laparoscopic gastrointestinal surgery: a randomised trial.
Huang Q, Wang F, Liang C, et al. · Br J Anaesth 2023 · Randomized Controlled Trial
Sponsor: Avyxa Holdings
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.